Cala Health, a bioelectronic medical company developing wearable therapies for chronic diseases, announces two validating moments for the non-invasive prescription therapy for essential tremor (ET), Cala Trio.
Real-world evidence from a Veteran Affairs (VA) patient population presented at the MDS Virtual Congress on September 15 shows that Cala Trio dramatically reduces tremor movement and severity in veterans with ET. This novel research follows guidelines from the International Essential Tremor Foundation (IETF) outlining the device in a new, recommended therapeutic category for patients with ET.
Research highlighted in the MDS Virtual Poster Tour shows Cala Trio as a viable treatment option and alternative to the more invasive and costly traditional treatment options on the market for patients with ET. Main results of 58 VA patients followed during the study collected:
50% of patients experienced a two-fold improvement in tremor strength with one month of Cala Trio with 40 minutes of on-demand use.
88.1% significant tremor reduction in patients with severe tremor, 83.6% improvement in patients with moderate tremor strength and 79.6% improvement in mild tremor strength.
Dr. Kalea Colletta of Edward Hines Jr. VA Medical Center, Department of Neurology, said, âEssential tremor is one of the most common movement disorders in adults, but unfortunately it is faced with unsatisfactory treatment options – ineffective drugs and invasive surgery. I meet with patients from all walks of life and everyone deserves an easy-to-use therapy option to alleviate their symptoms of tremors. The evidence presented at the MDS virtual conference shows how personalized Cala Trio is and how effective it can be in treating patients with mild to severe symptoms of tremor. “
Cala Trio Therapy, a wrist-worn device calibrated to treat symptoms of tremors, provides electrical stimulation to the nerves in the wrist. These nerves project from the wrist to central brain networks that are responsible for creating hand tremors in ET. It is believed that stimulation of these nerves disrupts the central neural network, causing hand tremors and providing a temporary and meaningful reduction in tremors in the treated hand.
Katie Rosenbluth, Founder and Chief Science Officer of Cala Health, said: âWe are proud of the recognition that Cala Trio has received, from validation by the IETF as a new therapeutic area to the research that our device has shown at MDS as an effective treatment for those suffering from essential tremor. We are pleased to be recognized as a viable alternative to partially effective pharmacotherapy or brain surgery and to significantly improve the lives of ET patients. “
Cala Health’s cutting-edge and science-based ET treatment is a viable alternative to the more invasive and costly traditional treatment options on the market. As part of Cala Health’s mission to bring ET Therapy to consumers, a variety of payment options are available to meet the needs of as many patients as possible. Cala Trio is eligible as a qualified medical expense for health savings and flexible expense accounts.